Bone Age Maturation and Growth Outcomes in Young Children with CAH Treated with Hydrocortisone Suspension.

Heba Al-RayessO Yaw AddoElise PalzerMu'taz JaberKristin FleissnerJames HodgesRichard BrundageBradley S MillerKyriakie Sarafoglou

Published in: Journal of the Endocrine Society (2021)

-scores, allowed lower average and cumulative daily HC dose compared to HC tablets, and generated no significant differences in SDS in growth parameters in children with CAH at 4 years of age. Longitudinal studies of treating with smaller HC doses during childhood are needed.

Keyphrases

young adults
physical activity
bone mineral density
type diabetes
septic shock
childhood cancer
case control